Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2016

View Archived Issues

Inactivating variants in ANGPTL4 are associated with lower risk of coronary artery disease

Prosaposin-derived therapeutic cyclic peptide promotes tumor regression in ovarian cancer models

Bayer receives Japanese approval for Xofigo

Japanese approval for Kovaltry

ABHD2 as a new target for developing male contraceptives

New ursolic acid derivatives are effective as potential anti-inflammatory treatment

ORIG3N and Sharp Edge Labs establish drug discovery alliance

Redx Pharma patents Raf kinase inhibitors

GlaxoSmithKline discloses HUNK1 inhibitors

Hong Kong Polytechnic University develops antibacterial agents

Landsteiner Genmed reports compounds for the treatment of fat accumulation

Janssen R&D Ireland presents anti-influenza agents

The potential of dispiro-cycloalkanone compounds as antifilarial drug candidates

Regeneron and Bayer to jointly develop nesvacumab/aflibercept combination for eye diseases

Alder reports results from two trials of ALD-403 for migraine prevention

FDA issues complete response letter for Brintellix sNDA

Nucala approved in Japan

Ubenimex awarded orphan drug designation in E.U. for PAH

Kamada submits MAA for inhaled AAT therapy to treat AAT deficiency

Dr. Reddy's gains U.S. rights to Xenoport's XP-23829

Iterum licenses rights to novel anti-infective compound, secures series A financing

Phase III trials of encenicline for cognitive impairment in schizophrenia miss primary endpoints

Kanuma approved in Japan to treat patients with lysosomal acid lipase deficiency

CA4P given E.U. orphan status for treating neuroendocrine tumors

Imbruvica approved in Japan for chronic lymphocytic leukemia

AstraZeneca receives Japanese approval for Tagrisso

New dose and formulation of Malarone combination tablets receive Japanese approval

Novartis reports Japanese approval of Tafinlar and Mekinist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.